17-Allylamino-17-demethoxygeldanamycin- An Hsp90 inhibitor

17-Allylamino-17-demethoxygeldanamycin (17AAG) is a less toxic and more stable analog of geldanamycin (GA) [1]. Even though 17-AAG binding to Hsp90 is weaker than GA,17-AAG displays similar antitumor effects as GA and a better toxicity profile. 17-AAG is currently in phase I clinical trial in several centers worldwide. Preliminary data obtained from these trials demonstrate that antitumor activity is achieved at concentrations below the maximum tolerated dose [2].


Working concentration: 10 nM - 10 μM
CAS number: 75747-14-7
Formula: C31H43N3O8
Molecular weight: 586
Solubility: Soluble in DMSO (10 mg/ml)


- 5 mg or  25 mg


1. Schulte TW. & neckers LM., 1998. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4):273-9
2. Agnew Eb. et al. 2001. Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-43



Cat. Codeant-agl-5
Unit Size5 mg
Price For price or distributor address,
please select your country


Cat. Codeant-agl-25
Unit Size25 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".